Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer

Ralf-Dieter Hofheinz; Dirk Arnold; Markus Borner; Wolfgang Eisterer; Gunnar Folprecht; Michael Ghadimi; Ullrich Graeven; Birgit Grünberger; Holger Hebart; Susanna Hegewisch-Becker; Volker Heinemann; Ron Pritzkuleit; Claus Rödel; Holger Rumpold; Tanja Trarbach; Georg Maschmeyer; Bernhard Wörmann

doi:10.1159/000541376

Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer

Ralf-Dieter Hofheinz, Dirk Arnold, Markus Borner, Wolfgang Eisterer, Gunnar Folprecht, Michael Ghadimi, Ullrich Graeven, Birgit Grünberger, Holger Hebart, Susanna Hegewisch-Becker, Volker Heinemann, Ron Pritzkuleit, Claus Rödel, Holger Rumpold, Tanja Trarbach, Georg Maschmeyer, Bernhard Wörmann

Abstract

This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian, and Swiss Onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy for rectal cancers with high-risk features, (ii) treatment with neoadjuvant chemotherapy for patients with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high/dMMR rectal cancer, as well as (iv) the implementation of organ sparing treatment concepts. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options, and risks of individual treatment approaches.

Original language	English
Journal	Oncology Research and Treatment
Volume	47
Issue number	12
Pages (from-to)	610-615
Number of pages	6
ISSN	2296-5270
DOIs	https://doi.org/10.1159/000541376
Publication status	Published - 2024

Research Areas and Centers

Research Area: Center for Population Medicine and Public Health (ZBV)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000541376

Cite this

Hofheinz, R.-D., Arnold, D., Borner, M., Eisterer, W., Folprecht, G., Ghadimi, M., Graeven, U., Grünberger, B., Hebart, H., Hegewisch-Becker, S., Heinemann, V., Pritzkuleit, R., Rödel, C., Rumpold, H., Trarbach, T., Maschmeyer, G., & Wörmann, B. (2024). Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer. Oncology Research and Treatment, 47(12), 610-615. https://doi.org/10.1159/000541376

@article{eaa65c78e45b43b2a4b5ff6ea91254bd,

title = "Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer",

abstract = "This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian, and Swiss Onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy for rectal cancers with high-risk features, (ii) treatment with neoadjuvant chemotherapy for patients with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high/dMMR rectal cancer, as well as (iv) the implementation of organ sparing treatment concepts. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options, and risks of individual treatment approaches.",

author = "Ralf-Dieter Hofheinz and Dirk Arnold and Markus Borner and Wolfgang Eisterer and Gunnar Folprecht and Michael Ghadimi and Ullrich Graeven and Birgit Gr{\"u}nberger and Holger Hebart and Susanna Hegewisch-Becker and Volker Heinemann and Ron Pritzkuleit and Claus R{\"o}del and Holger Rumpold and Tanja Trarbach and Georg Maschmeyer and Bernhard W{\"o}rmann",

note = "{\textcopyright} 2024 S. Karger AG, Basel.",

year = "2024",

doi = "10.1159/000541376",

language = "English",

volume = "47",

pages = "610--615",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "12",

}

Hofheinz, R-D, Arnold, D, Borner, M, Eisterer, W, Folprecht, G, Ghadimi, M, Graeven, U, Grünberger, B, Hebart, H, Hegewisch-Becker, S, Heinemann, V, Pritzkuleit, R, Rödel, C, Rumpold, H, Trarbach, T, Maschmeyer, G & Wörmann, B 2024, 'Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer', Oncology Research and Treatment, vol. 47, no. 12, pp. 610-615. https://doi.org/10.1159/000541376

TY - JOUR

T1 - Guidelines of Onkopedia

T2 - What Is New? Locally Advanced Rectal Cancer

AU - Hofheinz, Ralf-Dieter

AU - Arnold, Dirk

AU - Borner, Markus

AU - Eisterer, Wolfgang

AU - Folprecht, Gunnar

AU - Ghadimi, Michael

AU - Graeven, Ullrich

AU - Grünberger, Birgit

AU - Hebart, Holger

AU - Hegewisch-Becker, Susanna

AU - Heinemann, Volker

AU - Pritzkuleit, Ron

AU - Rödel, Claus

AU - Rumpold, Holger

AU - Trarbach, Tanja

AU - Maschmeyer, Georg

AU - Wörmann, Bernhard

PY - 2024

Y1 - 2024

N2 - This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian, and Swiss Onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy for rectal cancers with high-risk features, (ii) treatment with neoadjuvant chemotherapy for patients with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high/dMMR rectal cancer, as well as (iv) the implementation of organ sparing treatment concepts. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options, and risks of individual treatment approaches.

AB - This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian, and Swiss Onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy for rectal cancers with high-risk features, (ii) treatment with neoadjuvant chemotherapy for patients with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high/dMMR rectal cancer, as well as (iv) the implementation of organ sparing treatment concepts. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options, and risks of individual treatment approaches.

U2 - 10.1159/000541376

DO - 10.1159/000541376

M3 - Scientific review articles

C2 - 39288743

SN - 2296-5270

VL - 47

SP - 610

EP - 615

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - 12

ER -

Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Fingerprint

Cite this